MedTrace Logo

Nicotinamide Riboside Clinical Trial for GWI

NCT05243290 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-07-24

No results posted yet for this study

Summary

In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).

Conditions

  • Gulf War Illness

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside

The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.

DIETARY_SUPPLEMENT

Placebo

Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Nova Southeastern University

    collaborator OTHER

  • Roskamp Institute Inc.

    lead OTHER

Principal Investigators

  • Laila Abdullah, PhD · The Roskamp Institute

  • Michael Hoffmann, MD · The Roskamp Institute

  • Nancy Klimas, MD · Nova Southeastern University

  • Amanpreet Cheema, PhD · Nova Southeastern University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
47 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-13
Primary Completion
2025-04-30
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05243290 on ClinicalTrials.gov